| Arbor Trace Health & Living Community | |
| 3701 Hodgin Rd, Richmond, Indiana 47374 | |
| (765) 939-3701 | |
| Name | Arbor Trace Health & Living Community |
|---|---|
| Location | 3701 Hodgin Rd, Richmond, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 101 |
| Occupancy Rate | 93.76% |
| Medicare ID (CCN) | 155481 |
| Legal Business Name | Riverview Hospital |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1639156706 |
| Organization Name | RIVERVIEW HOSPITAL |
| Doing Business As | ARBOR TRACE HEALTH & LIVING COMMUNITY |
| Address | 3701 Hodgin Rd, Richmond, IN 47374 |
| Phone Number | 765-939-3701 |
News Archive
CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
A study of 400 high school age children with a variety of fitness and fatness levels showed that fatter youths had unfavorable lipid profiles, including higher levels of triglycerides and higher ratios of total cholesterol to the protective HDL cholesterol or high density lipoprotein.
This patent, entitled "O,O'-Amidomalonato and N,O-Amidomalonato Platinum Complexes" is one of a series of patents and patent applications owned by Access which provides intellectual property protection to ProLindac and related tumor-targeted platinum compounds.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
A study of 400 high school age children with a variety of fitness and fatness levels showed that fatter youths had unfavorable lipid profiles, including higher levels of triglycerides and higher ratios of total cholesterol to the protective HDL cholesterol or high density lipoprotein.
This patent, entitled "O,O'-Amidomalonato and N,O-Amidomalonato Platinum Complexes" is one of a series of patents and patent applications owned by Access which provides intellectual property protection to ProLindac and related tumor-targeted platinum compounds.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 15.81 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 60.94 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.36 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.39 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 13.49 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.65 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.69 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.03 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 67.38 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.79 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.56 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 27.44 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.78 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.62 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.63 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 72.73 | 82.93 |
News Archive
CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
A study of 400 high school age children with a variety of fitness and fatness levels showed that fatter youths had unfavorable lipid profiles, including higher levels of triglycerides and higher ratios of total cholesterol to the protective HDL cholesterol or high density lipoprotein.
This patent, entitled "O,O'-Amidomalonato and N,O-Amidomalonato Platinum Complexes" is one of a series of patents and patent applications owned by Access which provides intellectual property protection to ProLindac and related tumor-targeted platinum compounds.
› Verified 4 days ago
Golden Living Center-golden Rule Location: 2330 Straight Line Pike, Richmond, Indiana 47374 Phone: (765) 966-7681 | |
Arbor Trace Health & Living Community Location: 3701 Hodgin Rd, Richmond, Indiana 47374 Phone: (765) 939-3701 | |